TY - JOUR
T1 - Effects of imatinib on glycemic and lipid profiles
T2 - a retrospective cohort study
AU - Markovits, Noa
AU - Kurnik, Daniel
AU - Friedrich, Carmel
AU - Gueta, Itai
AU - Halkin, Hillel
AU - David, Sara
AU - Lomnicky, Yossi
AU - Topol, Yael
AU - Tirosh, Amir
AU - Loebstein, Ronen
N1 - Publisher Copyright:
© 2022 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022
Y1 - 2022
N2 - Despite a favorable effect of imatinib on glucose metabolism in animal models, human reports are inconsistent. We retrospectively studied the long-term effect of imatinib on fasting plasma glucose (FPG), glycated hemoglobin (HbA1C), LDL-cholesterol (LDL), and triglycerides (TGs) in a large HMO cohort of patients initiating therapy. In patients with diabetes (n = 118), significant reductions in HbA1c (0.53%, IQR 0.09, 1.19; p <.001) and FPG (10.2 mg/dL, IQR −3.5, 32.2; p <.001), independent of demographics and of glucose-lowering drugs utilization, were observed during the first year of imatinib treatment. Significant reductions in LDL (17.8 mg/dL, IQR −1.3, 34.0; p <.001) and TG (25.0 mg/dL, IQR −2.3, 58.3; p <.001), also independent of demographics and of statin utilization, were evident in the entire cohort (n = 611) during the first imatinib year. All reductions persisted during the second treatment year. To conclude, imatinib is associated with durable metabolic benefits, which may guide TKI choice in patients with cardiovascular co-morbidities.
AB - Despite a favorable effect of imatinib on glucose metabolism in animal models, human reports are inconsistent. We retrospectively studied the long-term effect of imatinib on fasting plasma glucose (FPG), glycated hemoglobin (HbA1C), LDL-cholesterol (LDL), and triglycerides (TGs) in a large HMO cohort of patients initiating therapy. In patients with diabetes (n = 118), significant reductions in HbA1c (0.53%, IQR 0.09, 1.19; p <.001) and FPG (10.2 mg/dL, IQR −3.5, 32.2; p <.001), independent of demographics and of glucose-lowering drugs utilization, were observed during the first year of imatinib treatment. Significant reductions in LDL (17.8 mg/dL, IQR −1.3, 34.0; p <.001) and TG (25.0 mg/dL, IQR −2.3, 58.3; p <.001), also independent of demographics and of statin utilization, were evident in the entire cohort (n = 611) during the first imatinib year. All reductions persisted during the second treatment year. To conclude, imatinib is associated with durable metabolic benefits, which may guide TKI choice in patients with cardiovascular co-morbidities.
KW - CML
KW - Imatinib
KW - diabetes mellitus
KW - dyslipidemia
UR - http://www.scopus.com/inward/record.url?scp=85129802600&partnerID=8YFLogxK
U2 - 10.1080/10428194.2022.2068003
DO - 10.1080/10428194.2022.2068003
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 35475716
AN - SCOPUS:85129802600
SN - 1042-8194
VL - 63
SP - 2224
EP - 2232
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 9
ER -
